CN104140414B - 阿昔替尼晶型的制备方法 - Google Patents
阿昔替尼晶型的制备方法 Download PDFInfo
- Publication number
- CN104140414B CN104140414B CN201310165500.6A CN201310165500A CN104140414B CN 104140414 B CN104140414 B CN 104140414B CN 201310165500 A CN201310165500 A CN 201310165500A CN 104140414 B CN104140414 B CN 104140414B
- Authority
- CN
- China
- Prior art keywords
- pazopanib
- crystal form
- hours
- preparation
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310165500.6A CN104140414B (zh) | 2013-05-07 | 2013-05-07 | 阿昔替尼晶型的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310165500.6A CN104140414B (zh) | 2013-05-07 | 2013-05-07 | 阿昔替尼晶型的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104140414A CN104140414A (zh) | 2014-11-12 |
CN104140414B true CN104140414B (zh) | 2018-12-11 |
Family
ID=51849764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310165500.6A Active CN104140414B (zh) | 2013-05-07 | 2013-05-07 | 阿昔替尼晶型的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104140414B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113943271B (zh) * | 2020-07-15 | 2023-11-14 | 鲁南制药集团股份有限公司 | 一种阿昔替尼晶型及其制备方法 |
CN114685436B (zh) * | 2020-12-25 | 2022-12-02 | 鲁南制药集团股份有限公司 | 阿昔替尼糖精共晶水合物 |
CN114685466B (zh) * | 2020-12-26 | 2023-06-13 | 鲁南制药集团股份有限公司 | 一种阿昔替尼共晶盐 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006048751A1 (en) * | 2004-11-02 | 2006-05-11 | Pfizer Inc. | Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole |
WO2006123223A1 (en) * | 2005-05-19 | 2006-11-23 | Pfizer Inc. | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
WO2008094484A2 (en) * | 2007-01-30 | 2008-08-07 | Schering Corporation | Pharmaceutical compositions and methods of using temozolomide and multi-targeted kinase inhibitors |
-
2013
- 2013-05-07 CN CN201310165500.6A patent/CN104140414B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006048751A1 (en) * | 2004-11-02 | 2006-05-11 | Pfizer Inc. | Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole |
WO2006123223A1 (en) * | 2005-05-19 | 2006-11-23 | Pfizer Inc. | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
WO2008094484A2 (en) * | 2007-01-30 | 2008-08-07 | Schering Corporation | Pharmaceutical compositions and methods of using temozolomide and multi-targeted kinase inhibitors |
Non-Patent Citations (1)
Title |
---|
The Challenges of Developing an API Crystallization Process for a Complex Polymorphic and Highly Solvating System.PartI;Brian P. Chekal et al.;《Organic Process Research&Development》;20091104;第13卷(第6期);1327-1337 * |
Also Published As
Publication number | Publication date |
---|---|
CN104140414A (zh) | 2014-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101412700B (zh) | 非布司他的晶型及其制备方法 | |
TWI597277B (zh) | 一種酪胺酸激酶抑制劑的二馬來酸鹽的第i型結晶及製備方法 | |
WO2011095059A1 (zh) | 达沙替尼多晶型物及其制备方法和药物组合物 | |
CN110092745B (zh) | 一种含芳环的化合物及其应用 | |
EP3255046B1 (en) | Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor | |
CN104140414B (zh) | 阿昔替尼晶型的制备方法 | |
CN103833755A (zh) | 阿哌沙班晶型b及其制备方法 | |
CN103059013B (zh) | 达沙替尼一水合物的晶型及其制备方法 | |
CN106478636B (zh) | 替格瑞洛晶型及制备方法 | |
WO2021000687A1 (zh) | Pac-1晶型的制备方法 | |
CN105992769B (zh) | 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体 | |
CN107405350A (zh) | 一种含有吡啶并嘧啶类衍生物或其可药用盐的药物组合物 | |
TWI695004B (zh) | 經取代的氨基吡喃衍生物之晶型 | |
CN105503838B (zh) | 曲沙他滨的合成及其晶型 | |
CN110964017A (zh) | 瑞博西尼单琥珀酸盐的多晶型物及其制备方法和用途 | |
EP2860184B1 (en) | Dihydrogenphosphate salt of Tenofovir disoproxil | |
US11254645B2 (en) | Method for preparing tolimidone on large scale | |
CN109053732B (zh) | 一种对氟取代含哒嗪酮结构的螺[吲哚嗪-吡唑啉]衍生物及其制备方法与应用 | |
CN105085514B (zh) | 马来酸甲麦角新碱化合物及其制备方法 | |
CN103450099B (zh) | 阿那曲唑及其一水合物的新晶型、制备和用途 | |
CN106065016A (zh) | 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法 | |
CN108602817B (zh) | 二肽基肽酶-iv抑制剂的苯甲酸盐的晶型 | |
US20050215600A1 (en) | Polymorphs of torsemide hydrochloride and process for production thereof | |
CN113214245A (zh) | 一种含氮化合物的晶型 | |
WO2017129024A1 (zh) | 一种维利帕尼晶型a及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
CB02 | Change of applicant information |
Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant after: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant before: JIANGSU HANSOH PHARMACEUTICAL GROUP LIANYUNGANG HONGCHUANG PHARMACEUTICAL Co.,Ltd. |
|
COR | Change of bibliographic data | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB02 | Change of applicant information |
Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant before: Jiangsu best Pharmaceutical Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant after: Jiangsu best Pharmaceutical Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160323 Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Address before: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant before: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |